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In 1983, a young man inhaled accidentally a large amount of plutonium and americium. This case was carefully followed until
2013. Since no decorporation measures had been taken, the undisturbed metabolism of Pu and Am can be derived from the data.
First objective was to determine the amount of inhaled radionuclides and to estimate committed effective dose. In vivo and excre-
tion measurements started immediately after the inhalation, and for quality assurance, all types of measurements were performed
by different labs in Europe and the USA. After dose assessment by various international groups were completed, the measure-
ments were continued to produce scientific data for model validation. The data have been analysed here to estimate lung absorp-
tion parameter values for the inhaled plutonium and americium oxide using the proposed new ICRP Human Respiratory Tract
Model. As supplement to the biokinetic modelling, biological data from three different cytogenetic markers have been added.
The estimated committed effective dose is in the order of 1 Sv. The subject is 30 y after the inhalation, of good health, according
to a recent medical check-up.
HISTORYOF THE INHALATION CASE
A first paper describing the details of the accident, the
early measurements and dose estimates of the Pu/Am
inhalation case of 1983 at the former Federal Institute
for Reactor Research in Switzerland has been pub-
lished in 2007(1). Immediately after accidental inhal-
ation by a 26-y-old male technician, dose estimates
were of primary interest. The results of measurements
performed in various labs were used by several organisa-
tions for testing their internal dosimetry programmes for
actinides. Later on, this case became mainly of scientific
interest since no chelating agent was used and, even
after 30 y, in vivo and excretion measurements were still
possible. Fortunately, the person concerned accepted
all these measurement procedures. Over the last few
years, organ measurements were performed with
highly specialised instruments at Karlsruhe Institute
for Technology (KIT)(2) and the excretion measure-
ments were done again at Paul Scherrer Institute
(PSI)(1). In addition to all the physical measure-
ments, current cytogenetic analyses were performed
at Federal Office for Radiation Protection(3) to com-
plete scientific data by biological studies.
RECENT IN VIVO MEASUREMENTS
Instruments and method
Recent in vivo measurements have been performed at
KIT Karlsruhe using a system of four HPGe detec-
tors(2). Two detector configurations were used: a
mixed one to monitor four organs (left lung, right
lung, liver and knee), and a configuration specific for
the skeleton (two detectors around the skull and two
detectors for the knees). The measurement time was
4000 s per configuration. The net area of the peaks
was estimated according to ISO 28 218. The calcula-
tion of the activity for 241Am in each organ was per-
formed using both ICRP Man and ICRP Female as
calibration phantoms, and the calibration data were
obtained using MCNPX(4) after a validation of the
method(2). The analysis of the data was performed first
for the mixed configuration; the results were used to
correct the calculations for the skeleton configuration.
The calculation of the activities in the mixed con-
figuration was not performed using each detector in-
dependently, because it is known that a measurable
part of the counts is generated by the crosstalk
between neighbouring organs and detectors. Instead,
the direct and the indirect contributions and the four
peak areas were used to write a system of linear equa-
tions. The solution of the system consisted of the ac-
tivity in each organ.
DISCUSSION
The solution of the system of equations applied to the
mixed measurement configuration produced a negative
value of 241Am activity in the liver, independently from
the calibration phantom used, suggesting the lack of
241Am in the organ. The system was therefore rewritten
to exclude the liver and the solution calculated again.
The final data are shown in Table 1.
The activity in the lungs calculated using the mixed
configuration was used to correct the peaks recorded
in the detectors around the skull. This was performed
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by simulating with MCNPX the counting efficiency
for photons originated in the lungs and reaching the
detectors around the skull. The number of counts ori-
ginated by the skeleton was therefore lowered: the net
value was 3–5 % lower when using ICRP Male as
calibration phantom and 8–10 % lower for ICRP
Female. The different results can be explained by the
higher amount of muscles in ICRP Male that acts as
shield and lowers the cross-counting efficiency for the
detectors around the skull. The corrected activities
are listed in Table 2.
By comparing the results for the mixed detector con-
figuration with the results for the skeleton configuration,
it appears that the activity value for the skeleton is co-
herent only when using ICRP Female: the calibration
with ICRPMan produces a discrepancy of 30 %.
A partial explanation for the issue is related to the
MCNPX simulations and the quality of the models
used to reproduce the detectors: currently, they are
optimised only for the front face, not for the photons
impinging on the sides of the crystal. More accurate
models will be available in the future.
The placement of the detectors relative to the
subject affects the results heavily, and it is the most
probable cause of the discrepancy between skull and
knees measurements. Additional simulations found
the efficiency for the skull to decrease by 50 % for a
2-cm slide of the subject down the reclined stretcher
[see the pictures in (2)]. The placement of the detec-
tors was checked at the beginning, but not at the end
of the measurement sessions; therefore, an accurate
correction factor for the measurements around the
skull is not possible. A similar issue may affect the
data for the knees, but the effect is an order of magni-
tude smaller: the simulations showed a decrease in the
counting efficiency of at most 7 % for a slide of 2 cm.
INTERPRETATION OFMEASUREMENTS
This inhalation case has been analysed in the past by
different authors and has been used in an internal
dosimetry inter-comparison exercise(5). The analysis
did show a very long lung retention, which could only
in part be accounted for by assuming that the inhaled
material was very insoluble. A significantly slower
particle transport clearance mechanism in the lungs
had also to be assumed in order for the model predic-
tions to agree with the measurements.
The data have been analysed here, by using the fol-
lowing models:
† for deposition, particle transport and absorption
to blood in the respiratory tract, a revision of
the Human Respiratory Tract Model (HRTM)(6).
In the revised particle transport model, the mater-
ial deposited in the alveolar compartment clears
to the bronchial tree at a rate of mT ¼ 0.002 d21
and to the interstitial compartment at a rate of
mI ¼ 0.001 d21. The interstitial compartment
clears very slowly to the regional lymph nodes at
a rate of 0.00003 d21;
† for transit through the alimentary tract the ICRP-
30 model(7);
† for systemic biokinetics, the Leggett model for plu-
tonium(8) and the ICRP model for americium(9).
The isotopic composition of the inhaled aerosol was
estimated from measurements in January 1983 (4
months before the accident) on the fuel samples used
in the solution that was overheated and spread out in
the accident. The alpha activity composition is
recorded as 10 % 241Am, 9 % 238Pu, 55 % 239Pu and
26 % 240Pu. The 241Pu (beta) activity is 750 % of the
total alpha activity. The uncertainty on these mea-
surements is not known. The above isotopic compos-
ition is consistent with the activity ratio (238Pu þ
241Am)/(239Pu þ 240Pu) ¼ 0.24+ 0.05 calculated
from the early faecal samples. There are no faecal
measurements for 241Pu, but a previous laboratory
record gives the 241Pu activity as 655 % of the total
alpha activity whereas all the alpha activities are
within a few per cent from the values given above. The
reason of the discrepancy for 241Pu is not known.
As in the previous analysis, an effective AMAD(10)
(Activity Median Aerodynamic Diameter) of 5 mm
has been estimated from early lung and early faecal
excretion data (including the activity that would have
appeared in the faeces if it had not been not removed
with a nasal swab and a bronchial slime before the
first chest measurement was done(1)). This value has
been used to calculate the fractions of material
Table 1. Activities calculated for the mixed configuration,
according to the calibration phantom used.
Organ ICRP Female [Bq] ICRPMan [Bq]
Skeletona 152 288
Lung leftb 60 73
Lung rightb 59 77
Liver 0 0
aBased on knee measurements.
bThe calibration phantom did not distinguish between lung
and thoracic lymph nodes.
Table 2. Activities calculated for the skeleton-specific
configuration, according to the calibration phantom used.
Organ measured ICRP Female [Bq] ICRPMan [Bq]
Knee 103 216
Knee 141 270
Average knees 122 243
Skull left 176 556
Skull right 184 449
Average skull 180 503
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deposited in each of the lung regions. The calculated
activity deposited in the nasal region has been
adjusted by subtracting the amount that was removed
immediately after the intake by nose swab. This cor-
rection does not affect the estimate of the effective
dose but only the fit to the very early faecal data.
Particles deposited in the lungs are cleared by two
competing mechanisms, by particle transport (to the
gut and to the lymph nodes) and by absorption to
blood of the dissolving material. For the latter, fr indi-
cates the fraction dissolved rapidly at the rate sr,
whereas the complementary fraction (1 2 fr) is dis-
solved slowly at the rate ss. A fraction fb of the dissolved
material may not be absorbed directly into blood and
could bind temporarily (sb . 0) or permanently (sb ¼
0) to lung tissues. As mentioned, the fraction (1 2 fb) is
available to be absorbed to blood at the rates sr and ss.
Absorption of material from the respiratory tract to
blood was shown to be slow in previous analysis. The
inhaled material was initially assumed to be ‘type S’
solubility(11), with absorption parameter values: fr ¼
0.001, sr ¼ 1 d21, ss ¼ 0.001 d21, and a bound state
was assumed with fb ¼ 0.002 and sb ¼ 0 d21(6, 12).
Note that the bound state does not play a significant
role in the long-term retention in the lungs because
the material is relatively insoluble. The gut uptake
fraction was kept fixed to its default value of f1 ¼ 5
1024 for type S material.
Measurement errors were assumed to be log-normally
distributed. The geometric standard deviations, or scatter-
ing factors, for the different datasets were either estimated
from the data, as described by Marsh et al.(13), or
based on the default values given in the IDEAS
guidelines(10). The values for the scattering factors were
1.2, 1.6 and 2.4 for chest, urine and faecal measure-
ments and 2 for liver and skeleton.
The agreement between measurements and model
predictions was poor when using default parameter
values, and the following changes to the models were
introduced to improve the fit to the data:
† the particle transport in the alveolar–interstitial
region was reduced;
† the absorption parameter values of the inhaled
material were optimised, either assuming that
they were the same for Am and Pu (i.e. shared
values) or that they were different (i.e. independ-
ent);
† the isotopic activity composition was allowed to
vary;
† the transfer rates from blood to urinary bladder
were varied in order to improve the fit to the skel-
eton and liver measurements.
The changes were applied by finding optimal model
parameter values using the maximum-likelihood
method. To address first the issue of activity balance,
only chest and excretion data were used. Liver and
skeleton data were included only in the last stage of
the optimisation. The agreement between model pre-
diction and measurements improved significantly, in
terms of chi-squared, for each of the above changes
(Table 3).
The adoption of the revised HRTM model(6)
improves the fit to lung and faecal excretion data,
compared with the previous HRTM(11), but a further
reduction of the particle transport rate from the al-
veolar region to the bronchiolar needs to be applied,
from mT ¼ 2`  1023 d21 to mT ¼ 3`  1024 d21. The
optimal value for the rate to the interstitial regions
(mI¼8.5` 1024 d21) differs only slightly from the
default value (mI ¼ 1`  1023 d21). The changes may
also be expressed as an increase of the so-called
sequestered fraction in the alveolar–interstitial
region, mI/(mI þ mT) from 0.33 to 0.74 and in the
slowdown of the clearance to the gut. This value is
relatively high but close to the upper limit of the 68 %
probability range for the inter-subject variation: (0.2,
0.7)(14). Assuming that americium is more soluble
than plutonium in the lungs improves the overall pre-
diction for urine excretion, although the very late
americium excretion remains slightly overestimated.
The rapid and slow absorption rates sr and ss for plu-
tonium are not well determined by the data, and it
would be possible to assume the same values of sr and
ss (shared values) for both Am and Pu without affect-
ing significantly the fit to the data. However, a much
better fit is obtained when the values for the rapid
fraction fr are optimised independently. The optimal
shared values are sr ¼ 0.2 d21 and ss ¼ 5`  1025 d21,
and fr ¼ 0.0014 for Pu and fr ¼ 0.05 for Am. The
result might be interpreted as an indication that
Table 3. Lung absorption parameters, committed effective
dose (CED) and organ doses (equivalent doses and per cent
contribution to the effective dose) for each added changes in
the optimisation.
PT þ
AbsP
þ isotopic
composition
þ Blood–
UB
fr (Pu) 0.0014 0.0017 0.004
fr (Am) 0.05 0.04 0.08
sr (d
21) 0.21 0.19 0.32
ss (10
25 d21) 5 5 7
CED (Sv) 1.3 1.1 1.2
Lung
[Sv (%)]
8.3 (77) 6.8 (74) 6.3 (67)
Liver 2.3 (7) 2 (7) 3 (10)
Bone surface 10 (8) 9 (8) 14 (12)
R.B.M. 0.5 (5) 0.5 (5) 0.7 (7)
x2TOT
(236 data)
261 232 212a
x2LUNG
(17 data)
38 16 12
a242 data, including skeleton (3) and liver (3) data.
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initially americium dissolves faster. Americium oxide
is generally more soluble than plutonium oxide(15),
but it is usually also considered that the rate at which
a particle dissociates is determined by the particle
matrix and therefore the dissolution parameter values
for americium and plutonium should be similar if
they belong to the same matrix. An interpretation of
the above result could possibly be provided by a better
knowledge of the physicochemical properties of the
inhaled material.
The overall fit is not sufficiently good, and this is
mainly due to the model prediction being ‘pulled’ in
opposite directions by chest and urine data.
An estimate of the isotopic composition of the
inhaled material is necessary to determine the initial
amount of americium and plutonium (isotopes)
deposited in the lungs. The values given above have
been considered as fixed in previous analysis. Based
on the available information, the authors assumed
here a relative error of 10 % and used it for a con-
strained optimisation. This would be equivalent to
introduce a prior distribution for the isotopic frac-
tions within a Bayesian framework.
The result of the optimisation, 13 % 241Am, 9 %
238Pu, 53 % 239Pu, 25 % 240Pu and 660 % 241Pu,
shows that the complete set of data and the models
used might be more consistent with a different isotop-
ic composition. However, the ratio (238Pu þ 241Am)/
(239Pu þ 240Pu) ¼ 0.25 is still compatible with the es-
timate 0.24+0.05 based on the early faecal measure-
ments. The lower beta activity (241Pu) also cannot be
completely excluded because of the two different
values given in the laboratory records.
The previous adjustments to the models improve
significantly the overall agreement between model
prediction and experimental data, except for liver and
skeleton. The reasons for the discrepancy could be
various, but to improve the fit to the liver and skeleton
data, it is necessary to modify systemic parameter
values. A sensitivity analysis shows that reducing the
amount transferred from blood to bladder is the most
effective in ensuring a good fit to the two systemic
organ datasets and improving further the agreement
with the urine data. The main effect is an increase of
the dose to internal organs, because more activity is
retained in the body instead of being excreted through
urine, and an adjustment of the lung absorption para-
meters. Note that this effect is achieved even if liver
and skeleton data are not included in the fitting
because it is mainly driven by the urine data. The rates
from blood to urinary bladder have been changed by
keeping constant the removal half-time from blood. A
constraint equivalent to a lognormal prior distribution
with geometric standard deviation equal to log(1.7)(16)
has been applied in the optimisation.
Table 3 shows how the optimal parameter values,
doses and chi-squared did vary when the changes [par-
ticle transport (PT) plus absorption parameters (AbsP),
isotopic composition, blood to urinary bladder] were
applied sequentially.
LUNGABSORPTION PARAMETERS
The maximum-likelihood procedure used for the
parameters estimation indicates that the shared par-
ameter sr and fr for Pu are less well defined by the
data than the other parameters. The estimates of fr, sr
and ss are not significantly correlated between them
(jrj , 0.15) but show higher correlation with the esti-
mate of the blood-to-urinary bladder rate.
The uncertainty on the estimates of the lung ab-
sorption parameters has been further investigated by
using Bayesian Markov chain Monte Carlo sam-
pling(17). Lognormal prior distributions have been
assumed for the parameters, which were constraint in
the optimisation. ‘Non-informative’ priors (normal
distribution for the log-transformed variable with
s ¼ 2 and centred on the best-fit result) have been
used for all the other parameters. Most of the absorp-
tion parameters were well defined (Table 4) as the pos-
terior distribution was relatively narrow (compared
with the prior distribution) and approximately
centred on the best-fit value. The exceptions are the
fast-absorbed fraction fr for plutonium, for which
only an upper limit ( fr , 0.015) is clearly defined,
and for the shared parameter sr for which the lower
limit is better defined than the upper limit (sr . 0.2
d21). All set of measurements used in the analysis are
given in the Annex (Tables A1–A5). Figures 1–4
show measurements and best-fit model predictions for
a subset of the datasets. As shown in Figure 1, most of
the 241Am activity predicted in chest at later times is
due to in-growth from 241Pu.
CYTOGENETICANALYSIS
In addition to the biokinetic modelling, three differ-
ent cytogenetic assays have been performed to analyse
diverse biomarkers of exposure in blood lymphocytes.
Dicentric assay
Up to now, the conventional analysis of dicentric
chromosomes (dicentric assay) is the most appropriate
Table 4. MCMC results for lung absorption parameters
and CED.
Mean value 95 % probability interval
fr (Am) 0.08 0.04–0.12
fr (Pu) 0.003 ,0.015
sr (d
21) 0.4 0.17–5
ss (d
21) 8`  1025 6`  1025–1`  1024
CED (Sv) 1.2 1.0–1.35
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assay to estimate a dose in case of an acute irradi-
ation(18, 19). This assay was also used in a previous
examination of the same person years ago(1). In the
present study, a total of 1000 cells from Giemsa
stained slides were analysed. The observed frequency
of 2 dicentric chromosomes per 1000 cells was not sig-
nificantly different ( p . 0.05) in comparison with the
authors’ control value of 1.15 dicentric chromosomes
per 1000 cells. This result was to be expected because
of the 30-y time period between the first accidental
exposure and the current blood sampling. The bio-
logical half-life of lymphocytes with dicentric chro-
mosomes is assumed to be 3 y. Due to a detriment of
dicentric chromosomes during cell division, the yield
of lymphocytes in the circulating blood bearing this
biomarker will decrease in the course of time.
FISH assay (symmetrical translocations)
The yield of symmetrical translocations in 3017 cells
scored was significantly increased (23.8+5.0/1000
cells, FG (Genome equivalents) values) in compari-
son with an age-adjusted control group including 35
persons and 88 934 cells scored [7.5+0.51/1000 cells,
FG (Genome equivalent) values]. This aberration
type has the advantage to pass cell division without
major detriment and thus is more persistent. In conse-
quence, symmetrical aberrations are the indicator of
choice for past and chronic radiation conditions(20). In
the current case, the significant increase of symmetrical
translocations indicates an irradiation incident. Because
of the lack of an appropriate dose–effect curve for this
radiation quality (alpha particles) and the extreme long
time period since the exposure, a dose reconstruction
was considered to be not feasible.
Figure 4. 239Pu þ 240Pu in 24-h faecal excretion.
Figure 1. 241Am in chest. The dash-dotted curve shows the
predicted 241Am activity without taking into account of
in-growth from 241Pu.
Figure 2. 241Am þ 238Pu in 24-h urine excretion.
Figure 3. 239Pu þ 240Pu in 24-h urine excretion.
30-Y FOLLOW-UP OFA PU/AM INHALATION CASE
61
Micronucleus assay
For micronuclei, the increase observed in comparison
with the unexposed control group was ambiguous. In
fact, there was a significant increase in the mean value
of micronuclei compared with the control value;
however, there still was an overlap with the upper
dose interval of the non-irradiated control. The
reason is the relatively high and variable spontaneous
frequency of micronuclei in control cells, which tends
to increase with age and also shows gender depend-
ency(21). Additionally problematic is the lack of speci-
ficity of micronuclei, as they can also be caused by
chemical clastogenic agents. Therefore, the increase
found here cannot clearly be assigned to the radiation
accident; however, a relationship cannot be excluded.
In summary, the significant increase of symmetrical
aberrations, while no enhancement of dicentric chro-
mosomes is observed, provides evidence for a past ra-
diation exposure of the blood forming tissue and/or
ongoing chronic low dose exposure.
CONCLUSIONANDOUTLOOK
The Pu/Am inhalation case of 1983 has been studied
by colleagues in several institutions and described in
numerous papers including the publication of 2007(1),
the actual publication and many papers cited in both
publications. The aim of the full publication of all
data of this case is to make this information available
for internal dosimetry model evaluation and training
in internal dosimetry. It will depend on the availabil-
ity and willingness of the person involved whether the
series of measurements can be continued and the
results presented in a future update.
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ANNEX
Table A1. Chesta, faeces and urine measurements: 241Am.
Chest Faeces Urine
t (d) Bq t (d) Bq d21 t (d) Bq d21
0.1 390 1074 0.0180 2092 0.0023
1 310 1075 0.0300 2095 0.0036
3 230 1076 0.0170 2525 ,0.0015
6 240 1077 0.0070 2526 0.0051
15 230 1921 0.0130 2527 0.0034
34 230 1922 0.0460 2921 0.0027
38 260 1923 0.0150 2922 0.0019
44 230 2525 0.0170 2923 ,0.0015
160 220 2526 0.0050 6043 0.0050
164 230 2527 0.0130 6044 0.0020
357 220 2921 ,0.0015 6045 0.0050
1077 240 2922 0.0060 6859 0.0050
2925 180 2923 ,0.0015 6860 0.0030
2926 305b,c 6043 0.0040 6861 0.0030
3724 146c 6044 0.0040 6870 0.0030
3828 192c 6045 0.0020 6903 0.0021
5078 209c 6859 0.0010 10708 0.0049
6037 175b,c 6860 0.0020 10709 0.0019
10713 150d 6861 0.0020 10710 0.0016
10708 0.0023
10709 0.0004
10710 0.0021
aChest measurements may include counts from thoracic
lymph nodes, ribs and liver.
bData that have been excluded from the fitting.
cLung and lymph node activities were measured separately
and added together.
dSee text for description of measurement.
Table A2. Liver and skeleton measurements: 241Am.
Liver Skeleton
t (d) Bq t (d) Bq
2926 27 2926 57
3724 57a 3724 69
3828 24 3828 65
5078 17 5078 95
6037 95
10713 0 10713 243a
aData that have been excluded from the fitting.
Table A3. Faeces and urine measurements: 238Pu 1 241Am.
Faeces Urine
t (d) Bq d21 t (d) Bq d21
1 1500.000 1 0.1100
2 740.000 2 0.1000
3 74.000 13 0.0170
13 0.160 14 0.0150
20 0.190 21 0.0110
21 0.110 30 0.0056
30 0.120 31 0.0056
37 0.078 37 0.0056
43 0.074 43 0.0052
44 0.044 179 0.0037
179 0.120 180 0.0044
180 0.100 182 0.0059
182 0.093 183 0.0044
183 0.063 364 0.0037
365 0.081 365 0.0026
366 0.026 366 0.0015
369 0.110 369 0.0052
370 0.037 370 0.0071
371 0.041 371 0.0041
605 0.085 605 0.0026
606 0.080 606 0.0053
607 0.059 607 0.0022
6043 0.005 1074 0.0015
6044 0.005 1075 0.0033
6045 0.002 1076 0.0030
6859 0.001 1077 0.0030
6860 0.003 1921 0.0056
6861 0.003 1922 0.0046
1923 0.0038
2089 0.0045
2090 0.0040
2091 0.0028
3902 0.0026
5076 0.0040
6043 0.0060
6044 0.0030
6045 0.0060
6859 0.0060
6860 0.0040
6870 0.0040
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Table A4. Faeces and urine measurements: 239 1 240Pu.
Faeces Urine
t (d) Bq d21 t (d) Bq d21
1 5200.000 1 0.0110
2 3000.000 2 0.0410
3 440.000 13 0.0058
13 0.670 14 0.0037
20 0.960 21 0.0037
21 0.480 30 0.0037
30 0.670 31 0.0037
37 0.250 37 0.0056
43 0.260 43 0.0037
44 0.160 179 0.0048
179 0.590 180 0.0030
180 0.470 182 0.0037
182 0.310 183 0.0033
183 0.310 364 0.0045
365 0.340 365 0.0022
366 0.150 366 0.0019
369 0.440 369 0.0037
370 0.180 370 0.0048
371 0.180 371 0.0037
605 0.300 605 0.0026
606 0.300 606 0.0040
607 0.170 607 0.0022
6043 0.012 1074 0.0022
6044 0.013 1075 0.0037
6045 0.008 1076 0.0033
6859 0.004 1077 0.0056
6860 0.014 1921 0.0059
6861 0.007 1922 0.0053
1923 0.0066
2089 0.0071
2090 0.0049
2091 0.0067
3902 0.0034
5076 0.0090
6043 0.0110
6044 0.0100
6045 0.0160
6859 0.0100
6860 0.0100
6870 0.0090
Table A5. Faeces and urine measurements: 238 1 239 1 240Pu.
Faeces Urine
t (d) Bq d21 t (d) Bq d21
1074 0.0700 2525 0.0042
1075 0.1200 2526 0.0064
1076 0.0650 2527 0.0070
1077 0.0250 2921 0.0047
1921 0.0900 2922 0.0044
1922 0.1900 2923 ,0.0015a
1923 0.1000 3723 0.0100
2525 0.0470 3725 0.0090
2526 0.0170 6043 0.0130
2527 0.0380 6044 0.0100
2921 0.0050 6045 0.0170
2922 0.0130 6859 0.0100
2923 0.0030 6860 0.0100
3723 0.0150 6861 0.0090
3725 0.0110 6870 0.0100
6043 0.0130 6903 0.0090
6044 0.0140 10708 0.0090
6045 0.0090 10709 0.0054
6859 0.0040 10710 0.0040
6860 0.0140
6861 0.0080
10708 0.0060
10709 0.0017
10710 0.0063
aData that have been excluded from the fitting.
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